Evidence map›Paper›PMID 30584369›Full record

ReviewCancer management and research2018

MALAT1: a potential biomarker in cancer.

Zhi-Xing Li, Qiong-Ni Zhu, Hai-Bo Zhang, Yang Hu, Guo Wang, Yuan-Shan Zhu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer management and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 165 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
165citing papers in PubMed, 1 pooled it
8.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

165 citing papers in PubMed, 1 synthesis or guideline pooled it, 269 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Exosomal lncRNAsInternational journal of molecular sciences · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. An Interpretable Omics-to-Image Transformer Framework for Cancer Prognosis Prediction.Computational and structural biotechnology journal · 2026
    Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

105 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Zhi-Xing LiDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China, 207082@csu.edu.cn.
Qiong-Ni ZhuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China, 207082@csu.edu.cn.
Hai-Bo ZhangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China, 207082@csu.edu.cn.
Yang HuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China, 207082@csu.edu.cn.
Guo WangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China, 207082@csu.edu.cn.
Yuan-Shan ZhuDepartment of Medicine, Weill Cornell Medicine, New York, NY, 10065, USA, yuz2002@med.cornell.edu.
Central South University · CNCornell University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe research of long non-coding RNAs (lncRNAs) has become a new passion with the discovery of abundant new lncRNAs and extensive investigation of their roles in various diseases, especially in cancers. Metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) emerges as a hotspot, which has been reported to be involved in dysregulation of cell signaling and closely correlated with cancer development, progression, and response to therapy. This review is a brief update of the current knowledge related to the role of MALAT1 in cancer-associated molecular pathways and pathophysiology and possible determinants for MALAT1 to function as a biomarker, aiming to stimulate the basic investigation of lncRNA MALAT1 as well as its translation to clinical applications.

methodsWe have selected vast literature from electronic databases including studies associated with its clinical significance and the pivotal functions in cancer processes such as cell proliferation, apoptosis, metastasis, immunity, angiogenesis, and drug resistance.

resultsStudies have shown that aberrant expression of MALAT1 is related to cancer pathophysiology with the potential to be translated clinically and MALAT1 can regulate cancer processes by interacting with molecules, such as proteins, RNAs and DNAs, and further altering different signal pathways.

conclusionMALAT1 lncRNA promises to be a potential biomarker for cancer diagnosis as well as prognosis. Additionally, it might be a therapeutic target for human cancers.

Indexed as

biomarkercancer therapychemoresistancelncRNAMALAT1metastasissignal pathways

Identifiers

PMID30584369
PMCPMC6289210
OpenAlexW2903139824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.